Vivitrol® Non-Formulary
Prior Authorization Guidelines
(naltrexone for extended-release injectable suspension)

Maricopa County/Magellan
Updated 11/8/11

FDA Approved Indications:
  - Alcohol dependence
  - Opioid dependence

Medical Necessity Guidelines for Participation in the Vivitrol QIA
1. Adults 18 years or older; AND
2. At least 6 months of continuous Title XIX/XXI enrollment with Magellan of Arizona; AND
3. Is being treated for alcohol dependence and/or opioid dependence; AND
4. Has voluntarily abstained from alcohol for at least 4 days; AND
5. Has been opioid free for at least 7 days; AND
6. Has at least 2 inpatient service utilization periods within the last 12 months. (Includes level 1 acute or subacute detoxification, alcoholism or opioid related admissions or other behavioral health admission); AND
7. Recipient agrees to actively participate in a comprehensive substance abuse treatment program that includes psychosocial support; AND
8. Staff administering injection has completed product and injection training through a Magellan authorized training and will ensure recipient completes and carries a wallet card noting they are on injectable naltrexone
9. Does not have acute hepatitis or liver failure; AND
10. Is not currently receiving opioid analgesics or in acute opioid withdrawal; AND
11. Does not have a positive urine screen for opioids or failure to the naloxone challenge test; AND
12. Does not have a hypersensitivity to naltrexone or any component of the diluent; AND
13. Documented compliance concerns or non-adherence with oral naltrexone

References: